Log in or register to see all Alerts
New HTA Decisions in Germany
December 2020
Drug name
BRAFTOVI® (encorafenib/cetuximab)
Company
Pierre Fabre Pharma
Decision date
01/10/2020
Therapeutic area
Cancer
Therapeutic sub area
Colorectal cancer
G-BA decision date
15/12/2020
Orphan Drug?
No
Decision
Additional benefit not quantifiable
Indication
Adult patients with metastatic colorectal cancer with a rapidly-accelerated BRAF-V600E mutation who have received prior systemic therapy. Main comparators: Patient-specific therapy.
Decision Detail
Main study: BEACON CRC Main driver of decision: IQWiG concluded that there are no data available involving patients with a BRAF-V600E mutation as the study supplied by the company does not investigate the most appropriate comparators.
Summary
IQWiG concluded that there are no appropriate data available to complete a benefit assessment for the use of encorafenib/cetuximab in patients with metastatic colorectal cancer with a rapidly-accelerated BRAF-V600E mutation who have received prior systemic therapy.